An interventional study of FDG PET/CT and Usual Care in Occult Cancer, sponsored by Ottawa Hospital Research Institute. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Ottawa Hospital Research Institute · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 117 studies in Ischemic Stroke with a site in Canada — 32 open to participants now, 39 under way, 9 of them phase 3. Ischemic Stroke · Canada.
Among the 117 studies in Ischemic Stroke with a site in Canada, this one is the 78th largest by planned enrollment of the 90 interventional ones that give a count, is one of 9 that started in 2023, is one of 40 with no phase, reaches primary completion later than 21 of the 38 other live ones, and was the 91st registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →32 of the 117 studies in Ischemic Stroke with a site in Canada are open now. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 75+
Population Health Research Institute · Sites in Canada
Ages 18+
University of Calgary · Sites in Canada, Australia
Ages 18+
Regeneron Pharmaceuticals · Sites in Canada, United States
Ages 18+
Javelin Medical · Sites in Canada, United States, Brazil and 1 more country
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
117 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 21 · Phase 3 26 · Phase 4 7
First in 2000; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 275 across the 90 interventional studies, 275 across the 24 observational. Of the 71 that completed or were terminated, 25 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 117 have an industry lead sponsor. The 10 most frequent:
Ottawa Hospital Research Institute is the lead sponsor of 547 studies on the registry; 99 are open to participants now.
Ottawa Hospital Research Institute has 4 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
9 of the studies in Ischemic Stroke with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT06403267NoNO Inc.NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy | 2026-12 |
| NCT05724823University of British ColumbiaVirtual Physical Activity Seated Exercise - Phase 2 | 2026-12-31 |
| NCT06027788Icahn School of Medicine at Mount SinaiCTSN Embolic Protection Trial | 2027-04-01 |
| NCT06226805Basking Biosciences, Inc.Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 117 studies in Ischemic Stroke with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT (F-fluorodeoxyglucose positron emission/computed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Usual care plus FDG PET/CT
Diagnostic Test: FDG PET/CT
Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care)
Diagnostic Test: Usual Care
F-fluorodeoxyglucose positron emission/computed tomography
Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care
Participant Recruitment
Number of participants recruited
Time frame: Over 12 months
Eligibility Rate
percentage of screened patients who are eligible
Time frame: Over 12 months
Consent Rate
percentage of eligible patients who provide consent
Time frame: Over 12 months
Retention Rate
percentage of participants retained at follow-up
Time frame: Over 24 months
Study Completion Rate
percentage of participants who completed all study procedures
Time frame: Over 24 months
Adherence Rate
adherence to screening strategy
Time frame: Over 24 months
Screening time frame
time from diagnosis to screening
Time frame: Over 24 months
Reasons for participation
Reasons for accepting/declining participation
Time frame: Over 24 months
Usual care cancer screening strategies
Usual care cancer screening strategies ordered by treating physicians
Time frame: Over 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Jan 2028, 52 months after the start.
Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 52 months is above that.
Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jan 2027 → Jan 2028 and completion Jan 2027 → Jan 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ottawa Hospital Research Institute →